Company
Headquarters: Barcelona, Spain
Employees: 50
CEO: Mr. Javier Rivela-Rodriguez
€52.6 Million
EUR as of July 1, 2024
US$56.5 Million
Company | Market Cap (USD) |
---|---|
Thermo Fisher Scientific | $204.45 B |
Danaher | $177.21 B |
Siemens Healthineers AG | $63.84 B |
DexCom, Inc. | $45.21 B |
Lonza Group Ltd | $39.85 B |
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Pangaea Oncology, S.A., a medical services company, provides a range of services to cancer patients, and pharmaceutical and biotech clients worldwide. It offers molecular diagnostics, such as mutation analysis in tumor tissue and blood, gene amplification and translocation testing, immunohistochemistry, and gene expression; clinical trials; in vitro drug profiling, including MTT proliferation assays, Western blotting, colony formation, migration and invasion assays, and gene silencing; and Dx platform, which performs companion diagnostic platform validation, validation against commercially available platforms, and Ad-hoc R+D for diagnostics companies. The company also provides biomarker discovery to identify novel targets for targeted therapies in pre-clinical development. Pangaea Oncology, S.A. was founded in 2007 and is based in Barcelona, Spain.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Pangaea Oncology SA has the following listings and related stock indices.
Stock: BME: PANG wb_incandescent